Foghorn Therapeutics Inc. banner

Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 5.68 USD 8.6% Market Closed
Market Cap: $321.2m

Wall Street
Price Targets

FHTX Price Targets Summary
Foghorn Therapeutics Inc.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FHTX is 11.56 USD with a low forecast of 9.09 USD and a high forecast of 14.7 USD.

Lowest
Price Target
9.09 USD
60% Upside
Average
Price Target
11.56 USD
104% Upside
Highest
Price Target
14.7 USD
159% Upside
Foghorn Therapeutics Inc. Competitors:
Price Targets
VINP
Vinci Partners Investments Ltd
16% Upside
CFFN
Capitol Federal Financial Inc
4% Upside
BTBT
Bit Digital Inc
208% Upside
SMCP
SMCP SA
24% Upside

Revenue
Forecast

N/A
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-28%
Average Miss
N/A
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-28%
Average Miss

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 4 years is 27%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FHTX's stock price target?
Price Target
11.56 USD

According to Wall Street analysts, the average 1-year price target for FHTX is 11.56 USD with a low forecast of 9.09 USD and a high forecast of 14.7 USD.

What is Foghorn Therapeutics Inc.'s Revenue forecast?
Projected CAGR
27%

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 4 years is 27%.

Back to Top